local_hospital

Herzklinik Ulm MVZ GmbH

Address
Magirusstrasse 49, Weststadt, 89077 Ulm, Germany

Cardiologicum Herzklinik Ulm MVZ GmbH

Cardiologicum Herzklinik Ulm MVZ GmbH is a specialized cardiovascular research center dedicated to advancing treatment strategies for complex cardiac and metabolic conditions. The center participates in pivotal multicenter clinical trials investigating innovative therapeutic approaches for patients with challenging cardiovascular disease profiles.

  • Advanced lipid management strategies for atherosclerotic cardiovascular disease
  • Heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF) with comorbid obesity
  • Novel pharmacological interventions including PCSK9 inhibitors and dual-agonist therapies

The center's research portfolio emphasizes the evaluation of next-generation treatments targeting hypercholesterolemia and cardiometabolic disease. Current investigations include comparative effectiveness studies of LDL-cholesterol lowering agents such as Inclisiran versus bempedoic acid, as well as breakthrough trials examining the cardiovascular benefits of maridebart cafraglutide in heart failure patients with elevated body mass index. This focus reflects the center's commitment to addressing the complex interplay between metabolic disorders and cardiovascular outcomes in high-risk patient populations.

Site Overview

assignment
5
connected trials
corporate_fare
4
sponsors
science
8
IMPs

Activity Indicator

Last 6 months

2
Trials started
+100% vs previous period.
1
Trials started 6–12 months ago
5
Total trials linked
Active
trending_upGrowing+100%
1
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status
lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
3
Sponsors (total)
4
Active sponsors
2

Sponsor Network

Top 2 by active trials.

lock +1 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 2 161 other sites in Germany

description
Trial volume
5
Outperforms 72% of sites
public
Therapeutic diversity
1areas
Outperforms 2% of sites
groups
Sponsor diversity
4sponsors
Outperforms 71% of sites

Therapeutic Area Benchmark — Germany

Select a therapeutic area to compare against other sites in Germany.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Germany

Market Share

Country: Germany

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Herzklinik Ulm MVZ GmbH

lock Showing 1 of 5 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
Comparative Efficacy of Inclisiran Sodium Versus Bempedoic Acid in LDL-C Reduction in Atherosclerotic Cardiovascular Disease PatientsNovartis Pharma GmbHPhase IIINot RecruitingJun 2024Jan 2026

IMP list

lock Showing 1 of 8 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Atorvastatin1Unknown2024-06-212024-06-21

Request feasibility information

Ask this centre about capacity, equipment and patient population.

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.